(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are ...

The global US Autoinjectors Market is projected to expand to a value of US$1.45 billion in 2030 from US$0.65 billion in 2024, ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

AbbVie Inc. appeared to find a sympathetic listener as it urged a three-judge panel Wednesday to block a Mississippi statute that requires manufacturers to steeply discount medicines to an unlimited ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...